Browse result page of AntiTbPdb
The total number entries retrieved from this search are 262
| ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| antitb_1463 | A3002-TB10.4 | IMYNYPAML | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1464 | A3002-TB10.4 | AMEDLVRAY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1465 | A3002-ESAT6 | AMASTEGNV | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1466 | A3002-Rv2958 | SARLAGIPY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1467 | A3002-Rv0447 | RMWELYLAY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1468 | A68-TB10.4 | HAMSSTHEA | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1469 | A68-TB10.4 | ANTMAMMAR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1470 | A68-Ag85B | LPQWLSANR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1471 | A68-Ag85B | WGAQLNAMK | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1472 | A68-Rv2958 | AAPEPVARR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1473 | A68-Rv2957 | LVYGDVIMR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2957 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2957 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1474 | A68-Rv0447 | AASAAIANR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1475 | B58-Ag85B | QTYKWETFL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1476 | Cw07-Ag85B | ANNTRLWVY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1609 | RR-11 | RKDVYRRRRRR | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis RIF-susceptible | MIC = 125 mg/L | in vitro | RAW 264.7 mouse macrophage | NA | HC50= > 2000 mg/L on Human RBC | NA | NA | Stimulate TNF-α production | Disrupt the mycobacterial membrane | NA | NA | NA | 2014 | 24411680 |
| antitb_1610 | RY-11 | RRRRRRRKDVY | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis RIF-susceptible | MIC = 125 mg/L | in vitro | RAW 264.7 mouse macrophage | NA | HC50= > 2000 mg/L on Human RBC | NA | NA | Stimulate TNF-α production | Disrupt the mycobacterial membrane | NA | NA | NA | 2014 | 24411680 |
| antitb_1613 | RR-11 | RKDVYRRRRRR | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis RIF-Resistance | MIC = 125 mg/L | in vitro | RAW 264.7 mouse macrophage | NA | HC50= > 2000 mg/L on Human RBC | NA | NA | Stimulate TNF-α production | Disrupt the mycobacterial membrane | NA | NA | NA | 2014 | 24411680 |
| antitb_1614 | RY-11 | RRRRRRRKDVY | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis RIF-Resistance | MIC = 125 mg/L | in vitro | RAW 264.7 mouse macrophage | NA | HC50= > 2000 mg/L on Human RBC | NA | NA | Stimulate TNF-α production | Disrupt the mycobacterial membrane | NA | NA | NA | 2014 | 24411680 |
| antitb_1615 | RY-11 | RRRRRRRKDVY | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis RIF-Resistance | MIC = 125 mg/L | in vitro | RAW 264.7 mouse macrophage | NA | HC50= > 2000 mg/L on Human RBC | NA | NA | Stimulate TNF-α production | Disrupt the mycobacterial membrane | NA | RR-11 Peptide(31.25 mg/L) + Rifampicin (1.95mg/L) | NA | 2014 | 24411680 |
| antitb_1616 | LK | LLKKLLKK | Free | Amidation | None | Linear | 8 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 125 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | NA | NA | 2015 | 26380930 |
| antitb_1617 | PP | PLLKKLLKKP | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 250 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | NA | NA | 2015 | 26380930 |
| antitb_1618 | CC | CLLKKLLKKC | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 250 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | NA | NA | 2015 | 26380930 |
| antitb_1619 | II | ILLKKLLKKI | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 62.5 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | NA | NA | 2015 | 26380930 |
| antitb_1620 | MM | MLLKKLLKKM | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 62.5 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | NA | NA | 2015 | 26380930 |
| antitb_1621 | WW | WLLKKLLKKW | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 62.5 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | NA | NA | 2015 | 26380930 |
| antitb_1622 | LK | LLKKLLKK | Free | Amidation | None | Linear | 8 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 62.5 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | Peptide + Rifampicin (0.98 μg/ml) | NA | 2015 | 26380930 |
| antitb_1623 | PP | PLLKKLLKKP | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 125 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | Peptide + Rifampicin (0.98 μg/ml) | NA | 2015 | 26380930 |
| antitb_1624 | CC | CLLKKLLKKC | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 250 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | Peptide + Rifampicin (0.98 μg/ml) | NA | 2015 | 26380930 |
| antitb_1625 | II | ILLKKLLKKI | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 15.6 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | Peptide + Rifampicin (0.98 μg/ml) | NA | 2015 | 26380930 |
| antitb_1626 | MM | MLLKKLLKKM | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 15.6 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | HC50= >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | Peptide + Rifampicin (0.98 μg/ml) | NA | 2015 | 26380930 |
| antitb_1627 | WW | WLLKKLLKKW | Free | Amidation | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC14468 | MIC = 0.98 μg/ml | in vitro | RAW 264.7 mouse macrophage | NA | >500 μg/ml | NA | NA | NA | Bacterial membrane pore formation | NA | Peptide + Rifampicin (0.98 μg/ml) | NA | 2015 | 26380930 |
| antitb_1653 | NA | WKWLKKWIK | Free | Free | None | Linear | 9 | L | Cationic | Synthetic | NA | Mycobacterium Tuberculosis | Mycobacterium tuberculosis H37Rv | IC90 = 1.5 μg/ml | in vitro | Human THP-1 cell lines | NA | NA | NA | NA | NA | Microbial membrane disruption | NA | NA | NA | 2016 | 26645944 |
| antitb_1674 | Wollamides 2 | WLL-allo-ING | NA | NA | Fourth amino acid is allolysine and form cyclic structure with 1st and 6th | Cyclic | 6 | D | Cationic | Natural | Streptomyces species MST-115088 | Mycobacterium bovis | Mycobacterium bovis BCG | NA | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial against staphylococcus aureus and bacillus subtilis | 2014 | 25229313 |
| antitb_1675 | Wollamides 5 | WLLVNG | Free | Free | NA | Cyclic | 6 | D | Cationic | Natural | Streptomyces species MST-115088 | Mycobacterium bovis | Mycobacterium bovis BCG | IC50 = 2.8 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial against staphylococcus aureus and bacillus subtilis | 2014 | 25229313 |
| antitb_1676 | Wollamides 6 | WLV-allo-ING | Free | Free | Fourth amino acid is allolysine and form cyclic structure with 1st and 6th | Cyclic | 6 | D | Cationic | Natural | Streptomyces species MST-115088 | Mycobacterium bovis | Mycobacterium bovis BCG | IC50 = 3.1 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial against staphylococcus aureus and bacillus subtilis | 2014 | 25229313 |
| antitb_1723 | SEQ ID NO 3 | NVTSIHSLL | Free | Free | None | Linear | 9 | L | NA | Protein Derived | From the proetins containing mycobacterial CD8 T cell epitopes | Mycobacterium tuberculosis | Mycobacterium tuberculosis | NA | In vitro | PBMcs | NA | NA | β2-microglobulin gene knowckout mice, TAP-1 null mutant mice and HSP-65 immunized mice | NA | IFN-γ release increases | By CD8 T cell response | NA | None | None | 2002 | US 2002/013197 |
| antitb_1726 | SEQ ID NO 8 | TATELNNAL | Free | Free | None | Linear | 9 | L | NA | Protein Derived | From the proetins containing mycobacterial CD8 T cell epitopes | Mycobacterium tuberculosis | Mycobacterium tuberculosis | NA | In vitro | PBMcs | NA | NA | β2-microglobulin gene knowckout mice, TAP-1 null mutant mice and HSP-65 immunized mice | NA | IFN-γ release increases | By CD8 T cell response | NA | None | None | 2002 | US 2002/013197 |
| antitb_1727 | SEQ ID NO 9 | RTISEAGQAM | Free | Free | None | Linear | 10 | L | NA | Protein Derived | From the proetins containing mycobacterial CD8 T cell epitopes | Mycobacterium tuberculosis | Mycobacterium tuberculosis | NA | In vitro | PBMcs | NA | NA | β2-microglobulin gene knowckout mice, TAP-1 null mutant mice and HSP-65 immunized mice | NA | IFN-γ release increases | By CD8 T cell response | NA | None | None | 2002 | US 2002/013197 |
| antitb_1728 | SEQ ID NO 10 | AYQGVQQKW | Free | Free | None | Linear | 9 | L | NA | Protein Derived | From the proetins containing mycobacterial CD8 T cell epitopes | Mycobacterium tuberculosis | Mycobacterium tuberculosis | NA | In vitro | PBMcs | NA | NA | β2-microglobulin gene knowckout mice, TAP-1 null mutant mice and HSP-65 immunized mice | NA | IFN-γ release increases | By CD8 T cell response | NA | None | None | 2002 | US 2002/013197 |
| antitb_1729 | SEQ ID NO 11 | SEAYQGVQQ | Free | Free | None | Linear | 9 | L | NA | Protein Derived | From the proetins containing mycobacterial CD8 T cell epitopes | Mycobacterium tuberculosis | Mycobacterium tuberculosis | NA | In vitro | PBMcs | NA | NA | β2-microglobulin gene knowckout mice, TAP-1 null mutant mice and HSP-65 immunized mice | NA | IFN-γ release increases | By CD8 T cell response | NA | None | None | 2002 | US 2002/013197 |
| antitb_1730 | SEQ ID NO 12 | SEAYQGVQQK | Free | Free | None | Linear | 10 | L | NA | Protein Derived | From the proetins containing mycobacterial CD8 T cell epitopes | Mycobacterium tuberculosis | Mycobacterium tuberculosis | NA | In vitro | PBMcs | NA | NA | β2-microglobulin gene knowckout mice, TAP-1 null mutant mice and HSP-65 immunized mice | NA | IFN-γ release increases | By CD8 T cell response | NA | None | None | 2002 | US 2002/013197 |
| antitb_1733 | Seq ID No 1 | GVENVSW | Free | Free | None | Linear | 7 | L | NA | Synthetic | From random peptide libraries diplayed on bacteriophage M15 | Mycobacterium tuberculosis | Mycobacterium tuberculosis | 100 μM completely inhibits the cahpaeron activity of Hsp 16.3 | In vitro | Mouse bone marrow derive dmacrophages and THP-1 | NA | NA | None | NA | NA | Inhibit chaperon activity of heat shock protein 16.3 (Hsp 16.3) | Heat shock protein (Hsp 16.3) | None | None | 2007 | US 2007/003721 |
| antitb_1734 | Seq ID No 2 | KMHATNH | Free | Free | None | Linear | 7 | L | NA | Synthetic | From random peptide libraries diplayed on bacteriophage M16 | Mycobacterium tuberculosis | Mycobacterium tuberculosis | 100 μM completely inhibits the cahpaeron activity of Hsp 16.3 | In vitro | Mouse bone marrow derive dmacrophages and THP-1 | NA | NA | None | NA | NA | Inhibit chaperon activity of heat shock protein 16.3 (Hsp 16.3) | Heat shock protein (Hsp 16.3) | None | None | 2007 | US 2007/003721 |
| antitb_1776 | Sesquin | KTCENLADTY | Free | Free | None | Linear | 10 | L | Cationic | Natural | Isolated from ground beans (Vigna sesquipedalis cv. ‘Ground Bean’) | Mycobacterium phlei | Mycobacterium phlei | IC50 = 87 ± 5 µM | In vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial, Antifungal | 2005 | 15949629 |
| antitb_1813 | E2 (also known as Bac8c) | RIWVIWRR | Free | Amidation | None | Linear | 8 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis strain H37Rv | MIC = 2.6 ± 0.34 g/mL | Both | NA | NA | NA | Male BALB/c mice | a significant reduction in bacilli loads | NA | Disruption of cell wall and membrane | cell wall and membrane | NA | Antibacterial (P.aeruginosa) | 2012 | 23141114 |
| antitb_1832 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 11.3 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
| antitb_1833 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X004439 | MIC = 9.3 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
| antitb_1834 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X004244 | MIC = 16.9 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
| antitb_1835 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X005282 | MIC = 9.6 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
| antitb_1836 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X005319 | MIC = 19.2 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |